Darbufelone mesilate. Antiarthritic lipoxygenase inhibitor cyclooxygenase-2 inhibitor

Drugs of the Future

Volumn 24, Issue 8, 1999, Pages 853-857

  Martin, L ^a   Rabasseda, X ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; DARBUFELONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONFORMATION; DRUG EFFECT; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; MONKEY; NONHUMAN; PROSTAGLANDIN SYNTHESIS INHIBITION; RAT; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION;

EID: 0032818955     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1999.024.08.534526     Document Type: Article

References (23)

1. Cetenco, W.A., Connor, D.T., Sircar, J.C., Sorenson, R.J., Unangst, P.C. (Warner-Lambert Co.). 3,5-Di-tertiary-butyl-4-hydroxyphenyl-methylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents. EP 449216, JP 92221371, US 5143928.
2. Unangst, P.C., Connor, D.T., Cetenko, W.A., Sorenson, R.J., Sircar, J.C., Wright, C.D., Schrier, D.J., Dyer, R.D. Oxazole, thiazole, and imidazole derivatives of 2,6-di-tert-butylphenol as dual 5-lipoxygenase and cyclooxygenase inhibitors. Bioorg Med Chem Lett 1993, 3: 1729-34.
3. Unangst, P.C., Connor, D.T., Cetenko, W.A., Sorenson, R.J., Kostlan, C.R., Sircar, J.C., Wright, C.D., Schrier, D.J., Dyer, R.D. Synthesis and biological evaluation of 5-[3,5-bis(1,1-dimethyl-ethyl)-4-hydroxyphenyl]methylene]oxazoles, -thiazoles, and -imidazoles: Novel dual 5-lipoxygenase and cyclooxygenase inhibitors with antiinflammatory activity. J Med Chem 1994, 37: 322-8.
4. Rabasseda, X. Lornoxicam, a new NSAID with an improved tolerability profile. Drugs Today 1999, in preparation.
5. Connor, D.T., Boschelli, D.H. Stud Med Chem 1996, 2: 47-86.
6. Dyer, R.D., Connor, D.T. Dual inhibitors of prostaglandin and leukotriene biosynthesis. Curr Pharm Design 1997, 3 (5): 463-72.
7. Dyer, R.D., Bornemeier, D.A., Cetenko, W.A., Ferin, M.A., Kuipers, P.J., Lesch, M.E., Schrier, D.J., Sircar, J.C., Wright, C.D. Biochemical pharmacology of PD 136095, a novel inhibitor of arachidonic acid metabolism. 6th Int Conf Inflamm Res Assoc (Sept 20-24, Pennsylvania) 1992, Abst P105.
8. Fujimori, T., Connor, D.T., Cetenko, W.A., Marletta, M.A., Hupe, D.J., Dyer, R.D. A novel antiinflammatory compound extends the lag phase of prostaglandin H synthase-2 (PGHS-2) kinetics. FASEB J 1996, 10(6): Abst 1495.
9. 2 synthase-2 (hPGHS-2) and inhibition of cyclooxygenase activity. FASEB J 1998, 12(8): Abst 440.
10. Song, Y., Connor, D.T., Doubleday, R. et al. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 1. Thiazolone and oxazolone series. J Med Chem 1999, 42: 1151-60.
11. Menetski, J.P., Herman, S.B., Chan, K.P., Sripaipan, T., Skronek, J., Gilbertsen, R.B. Phosphodiesterase (PDE)-3 and PDE-4 inhibition by the antiinflammatory drug darbufelone. FASEB J 1999, 13(4, Part 1): Abst 153.21.
12. Schrier, D.J., Cetenko, W.A., Dyer, R.D., Kuchera, S., Imre, K., Lesch, M.E., Okonkwo, G.C.N., Sircar, J.C., Wright, C., Conroy, M.C. The antiinflammatory and analgesic effects of (Z)-5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-2-imino-4- thiazolidinone (PD 136095), a novel dual inhibitor of 5-lipoxygenase and cyclooxygenase. 6th Int Conf Inflamm Res Assoc (Sept 20-24, Pennsylvania) 1992, Abst P112.
13. Guglietta, A., Lesch, C.A., Kraus, E.R., Dyer, R., Schrier, D., Sanchez, B. Effect of PGHS-2 inhibitors and other antiinflammatory drugs on healing of acetic acid-induced ulcer in rats. Dig Dis Week (May 10-16, Washington DC) 1997, Abst 4329.
14. Laemont, K., Schrier, D. Effects of the novel antiinflammatory drug, darbufelone, in streptococcal cell wall-induced arthritis in rats. FASEB J 1999, 13(5, Part 2): Abst 643.23.
15. Andress, L.D., Guttendorf, R.J. Pharmacokinetics (PK) and bioavailability of CI-1004, a novel antiinflammatory drug, in rats. Pharm Res 1994, 11(10, Suppl.): Abst PPDM 8064.
16. Loewen, G., Buckley, K., Guttendorf, R., Andress, L. Dose-and concentration-dependent induction of antipyrine clearance in beagle dogs by the antiinflammatory compound, PD 136095. Pharm Res 1992, 9(10, Suppl.): Abst PPDM 8156.
17. Loewen, G., Patel, B., Buckley, K., Connor, D., Mullican, M., Unangst, P. Structure-activity relationship of enzyme induction in beagle dogs within a series of antiinflammatory di-t-butylphenols. Pharm Res 1992, 9(10, Suppl.): Abst PPDM 8157.
18. Guttendorf, R.J., Andress, L., Okonkwo, G., Finkel, M., Schrier, D., Loewen, G. Pharmacokinetic and pharmacodynamic assessment of a novel antiinflammatory drug in early discovery. Pharm Res 1992, 9(10, Suppl.): Abst PPDM 8398.
19. Guttendorf, R.J., Andress, L., Okonkwo, G., Lesch, M., Finkel, M., Schrier, D., Loewen, G. Early preclinical pharmacokinetics and antiinflammatory pharmacodynamics of PD 136095. 6th Int Conf Inflamm Res Assoc (Sept 20-24, Pennsylvania) 1992, Abst P122.
20. Andress, L.D., Guttendorf, R.J. Pharmacokinetics (PK) and bioavailability of CI-1004, a novel antiinflammatory drug, in dogs. Pharm Res 1994, 11(10, Suppl.): Abst PPDM 8063.
21. Guttendorf, R.J., Andress, L.D. Pharmacokinetics (PK) and bioavailability of CI-1004, a new antiinflammatory drug, in monkeys. Pharm Res 1996, 13(9, Suppl.): Abst PPDM 8415.
22. Guttendorf, R.J., Andress, L.D., Shailer, P., Vassos, A.B. Single-dose Pharmacokinetics and dose proportionality of the antiinflammatory drug, CI-1004, in healthy subjects. Pharm Res 1997, 14(11, Suppl.): Abst 3471.
23. Guttendorf, R.J., Andress, L.D., Shailer, P., Vassos, A.B. Multiple-dose Pharmacokinetics of the antiinflammatory drug, CI-1004, in healthy subjects after 3-weeks of once-daily dosing. Pharm Res 1997; 14 (11, Suppl.): Abst. 3472.